25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Clinuvel Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyze Clinuvel together

I guess you are interested in Clinuvel Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Clinuvel Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Clinuvel (30 sec.)










1.2. What can you expect buying and holding a share of Clinuvel? (30 sec.)

How much money do you get?

How much money do you get?
$0.10
When do you have the money?
1 year
How often do you get paid?
70.0%

What is your share worth?

Current worth
$2.14
Expected worth in 1 year
$4.16
How sure are you?
90.0%

+ What do you gain per year?

Total Gains per Share
$2.13
Return On Investment
22.9%

For what price can you sell your share?

Current Price per Share
$9.28
Expected price per share
$8.78 - $9.51
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Clinuvel (5 min.)




Live pricePrice per Share (EOD)
$9.28
Intrinsic Value Per Share
$-0.17 - $0.70
Total Value Per Share
$1.97 - $2.84

2.2. Growth of Clinuvel (5 min.)




Is Clinuvel growing?

Current yearPrevious yearGrowGrow %
How rich?$110.6m$84.4m$26.2m23.7%

How much money is Clinuvel making?

Current yearPrevious yearGrowGrow %
Making money$20.5m$14m$6.5m31.8%
Net Profit Margin39.1%31.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Clinuvel (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#318 / 968

Most Revenue
#121 / 968

Most Profit
#50 / 968
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Clinuvel?

Welcome investor! Clinuvel's management wants to use your money to grow the business. In return you get a share of Clinuvel.

First you should know what it really means to hold a share of Clinuvel. And how you can make/lose money.

Speculation

The Price per Share of Clinuvel is $9.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Clinuvel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Clinuvel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.14. Based on the TTM, the Book Value Change Per Share is $0.51 per quarter. Based on the YOY, the Book Value Change Per Share is $0.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Clinuvel.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.404.3%0.404.3%0.272.9%0.293.1%0.151.6%
Usd Book Value Change Per Share0.515.5%0.515.5%0.333.6%0.323.5%0.202.1%
Usd Dividend Per Share0.030.3%0.030.3%0.020.2%0.020.2%0.010.1%
Usd Total Gains Per Share0.535.7%0.535.7%0.353.8%0.343.7%0.212.2%
Usd Price Per Share12.00-12.00-9.75-16.80-10.44-
Price to Earnings Ratio30.22-30.22-35.96-62.96-30.77-
Price-to-Total Gains Ratio22.58-22.58-28.00-56.70-44.00-
Price to Book Ratio5.62-5.62-5.98-15.28-14.27-
Price-to-Total Gains Ratio22.58-22.58-28.00-56.70-44.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.28
Number of shares107
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.02
Usd Book Value Change Per Share0.510.32
Usd Total Gains Per Share0.530.34
Gains per Quarter (107 shares)56.8636.26
Gains per Year (107 shares)227.45145.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1112162177138135
22243344415275280
33364967122413425
44486689830550570
5551082112537688715
6661299135245826860
77715151579529631005
888173218066011011150
999194820336712381295
10110216522607513761440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.03.00.070.0%7.016.00.030.4%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%14.09.00.060.9%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.00.03.070.0%7.00.016.030.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%14.09.00.060.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Clinuvel Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5060.5060%0.332+52%0.321+57%0.195+159%
Book Value Per Share--2.1362.1360%1.631+31%1.363+57%0.828+158%
Current Ratio--7.4387.4380%10.237-27%10.620-30%9.854-25%
Debt To Asset Ratio--0.1500.1500%0.128+18%0.110+37%0.113+32%
Debt To Equity Ratio--0.1770.1770%0.146+21%0.124+42%0.129+37%
Dividend Per Share--0.0260.0260%0.016+60%0.017+47%0.011+127%
Eps--0.3970.3970%0.271+46%0.287+38%0.146+173%
Free Cash Flow Per Share---0.013-0.0130%-0.006-58%0.040-133%0.014-196%
Free Cash Flow To Equity Per Share---0.042-0.0420%-0.025-41%0.020-311%0.023-283%
Gross Profit Margin--1.0001.0000%1.0000%0.961+4%1.0030%
Intrinsic Value_10Y_max--0.702--------
Intrinsic Value_10Y_min---0.165--------
Intrinsic Value_1Y_max--0.047--------
Intrinsic Value_1Y_min---0.012--------
Intrinsic Value_3Y_max--0.159--------
Intrinsic Value_3Y_min---0.040--------
Intrinsic Value_5Y_max--0.292--------
Intrinsic Value_5Y_min---0.072--------
Market Cap464963264.000-34%621791964.000621791964.0000%504820329.000+23%854843355.604-27%529592573.665+17%
Net Profit Margin--0.3910.3910%0.318+23%0.464-16%-0.333+185%
Operating Margin--0.6230.6230%0.557+12%0.547+14%-0.380+161%
Operating Ratio--0.4370.4370%0.462-6%0.486-10%1.397-69%
Pb Ratio4.344-29%5.6175.6170%5.979-6%15.283-63%14.267-61%
Pe Ratio23.367-29%30.21630.2160%35.959-16%62.960-52%30.774-2%
Price Per Share9.280-29%12.00012.0000%9.750+23%16.802-29%10.439+15%
Price To Free Cash Flow Ratio-695.967+23%-899.958-899.9580%-1728.150+92%-1177.538+31%-1413.541+57%
Price To Total Gains Ratio17.462-29%22.58122.5810%28.003-19%56.697-60%44.004-49%
Quick Ratio--12.23712.2370%16.881-28%16.082-24%12.362-1%
Return On Assets--0.1580.1580%0.145+9%0.205-23%0.034+361%
Return On Equity--0.1860.1860%0.166+12%0.229-19%0.030+521%
Total Gains Per Share--0.5310.5310%0.348+53%0.339+57%0.206+158%
Usd Book Value--110697980.553110697980.5530%84425900.513+31%69899479.170+58%42300924.450+162%
Usd Book Value Change Per Share--0.5060.5060%0.332+52%0.321+57%0.195+159%
Usd Book Value Per Share--2.1362.1360%1.631+31%1.363+57%0.828+158%
Usd Dividend Per Share--0.0260.0260%0.016+60%0.017+47%0.011+127%
Usd Eps--0.3970.3970%0.271+46%0.287+38%0.146+173%
Usd Free Cash Flow---690912.517-690912.5170%-292116.111-58%2016308.398-134%691139.116-200%
Usd Free Cash Flow Per Share---0.013-0.0130%-0.006-58%0.040-133%0.014-196%
Usd Free Cash Flow To Equity Per Share---0.042-0.0420%-0.025-41%0.020-311%0.023-283%
Usd Market Cap464963264.000-34%621791964.000621791964.0000%504820329.000+23%854843355.604-27%529592573.665+17%
Usd Price Per Share9.280-29%12.00012.0000%9.750+23%16.802-29%10.439+15%
Usd Profit--20578510.17820578510.1780%14038679.866+47%14926244.101+38%7551275.640+173%
Usd Revenue--52663254.22352663254.2230%44191669.141+19%34377444.076+53%20787998.483+153%
Usd Total Gains Per Share--0.5310.5310%0.348+53%0.339+57%0.206+158%
 EOD+3 -5MRQTTM+0 -0YOY+23 -125Y+19 -1710Y+23 -13

3.3 Fundamental Score

Let's check the fundamental score of Clinuvel Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1523.367
Price to Book Ratio (EOD)Between0-14.344
Net Profit Margin (MRQ)Greater than00.391
Operating Margin (MRQ)Greater than00.623
Quick Ratio (MRQ)Greater than112.237
Current Ratio (MRQ)Greater than17.438
Debt to Asset Ratio (MRQ)Less than10.150
Debt to Equity Ratio (MRQ)Less than10.177
Return on Equity (MRQ)Greater than0.150.186
Return on Assets (MRQ)Greater than0.050.158
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than504.050
Ma 20Greater thanMa 5011.351
Ma 50Greater thanMa 10011.158
Ma 100Greater thanMa 20010.463
OpenGreater thanClose9.280
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-08-30 23:48:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Clinuvel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 39.1%Β means thatΒ $0.39 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 39.1%. The company is making a huge profit. +2
  • The TTM is 39.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ39.1%TTM39.1%0.0%
TTM39.1%YOY31.8%+7.3%
TTM39.1%5Y46.4%-7.3%
5Y46.4%10Y-33.3%+79.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ39.1%-128.6%+167.7%
TTM39.1%-208.9%+248.0%
YOY31.8%-229.1%+260.9%
5Y46.4%-377.7%+424.1%
10Y-33.3%-503.2%+469.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Clinuvel is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 15.8% Return on Assets means thatΒ Clinuvel generatedΒ $0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 15.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 15.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.8%TTM15.8%0.0%
TTM15.8%YOY14.5%+1.3%
TTM15.8%5Y20.5%-4.7%
5Y20.5%10Y3.4%+17.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.8%-11.1%+26.9%
TTM15.8%-11.7%+27.5%
YOY14.5%-11.2%+25.7%
5Y20.5%-12.9%+33.4%
10Y3.4%-14.4%+17.8%
4.3.1.3. Return on Equity

Shows how efficient Clinuvel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 18.6% Return on Equity means Clinuvel generated $0.19Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 18.6%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 18.6%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ18.6%TTM18.6%0.0%
TTM18.6%YOY16.6%+2.0%
TTM18.6%5Y22.9%-4.3%
5Y22.9%10Y3.0%+19.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.6%-13.8%+32.4%
TTM18.6%-15.9%+34.5%
YOY16.6%-13.8%+30.4%
5Y22.9%-18.9%+41.8%
10Y3.0%-19.0%+22.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Clinuvel Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Clinuvel is operatingΒ .

  • Measures how much profit Clinuvel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • An Operating Margin of 62.3%Β means the company generated $0.62 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 62.3%. The company is operating very efficient. +2
  • The TTM is 62.3%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ62.3%TTM62.3%0.0%
TTM62.3%YOY55.7%+6.6%
TTM62.3%5Y54.7%+7.5%
5Y54.7%10Y-38.0%+92.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ62.3%-206.3%+268.6%
TTM62.3%-244.2%+306.5%
YOY55.7%-237.8%+293.5%
5Y54.7%-382.6%+437.3%
10Y-38.0%-498.7%+460.7%
4.3.2.2. Operating Ratio

Measures how efficient Clinuvel is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.44 means that the operating costs are $0.44 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.437. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.437. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.437TTM0.4370.000
TTM0.437YOY0.462-0.026
TTM0.4375Y0.486-0.049
5Y0.48610Y1.397-0.911
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4372.631-2.194
TTM0.4373.198-2.761
YOY0.4623.441-2.979
5Y0.4865.083-4.597
10Y1.3976.602-5.205
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Clinuvel Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Clinuvel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 7.44Β means the company has $7.44 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 7.438. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.438. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.438TTM7.4380.000
TTM7.438YOY10.237-2.800
TTM7.4385Y10.620-3.183
5Y10.62010Y9.854+0.766
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.4383.739+3.699
TTM7.4383.909+3.529
YOY10.2374.740+5.497
5Y10.6205.946+4.674
10Y9.8546.296+3.558
4.4.3.2. Quick Ratio

Measures if Clinuvel is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Quick Ratio of 12.24Β means the company can pay off $12.24 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 12.237. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.237. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.237TTM12.2370.000
TTM12.237YOY16.881-4.644
TTM12.2375Y16.082-3.845
5Y16.08210Y12.362+3.720
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2372.366+9.871
TTM12.2373.226+9.011
YOY16.8814.683+12.198
5Y16.0825.854+10.228
10Y12.3626.414+5.948
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Clinuvel Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ClinuvelΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Clinuvel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15Β means that Clinuvel assets areΒ financed with 15.0% credit (debt) and the remaining percentage (100% - 15.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.150. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.150. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.150TTM0.1500.000
TTM0.150YOY0.128+0.022
TTM0.1505Y0.110+0.041
5Y0.11010Y0.113-0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1500.340-0.190
TTM0.1500.346-0.196
YOY0.1280.304-0.176
5Y0.1100.365-0.255
10Y0.1130.382-0.269
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Clinuvel is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 17.7% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.177. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.177. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.177TTM0.1770.000
TTM0.177YOY0.146+0.030
TTM0.1775Y0.124+0.053
5Y0.12410Y0.129-0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1770.394-0.217
TTM0.1770.446-0.269
YOY0.1460.372-0.226
5Y0.1240.450-0.326
10Y0.1290.487-0.358
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Clinuvel generates.

  • Above 15 is considered overpriced butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A PE ratio of 30.22 means the investor is paying $30.22Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 23.367. Based on the earnings, the company is fair priced.
  • The MRQ is 30.216. Based on the earnings, the company is overpriced. -1
  • The TTM is 30.216. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD23.367MRQ30.216-6.849
MRQ30.216TTM30.2160.000
TTM30.216YOY35.959-5.744
TTM30.2165Y62.960-32.744
5Y62.96010Y30.774+32.186
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD23.367-2.299+25.666
MRQ30.216-2.484+32.700
TTM30.216-2.965+33.181
YOY35.959-3.475+39.434
5Y62.960-6.123+69.083
10Y30.774-6.242+37.016
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is -695.967. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -899.958. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -899.958. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-695.967MRQ-899.958+203.990
MRQ-899.958TTM-899.9580.000
TTM-899.958YOY-1,728.150+828.192
TTM-899.9585Y-1,177.538+277.580
5Y-1,177.53810Y-1,413.541+236.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-695.967-3.074-692.893
MRQ-899.958-3.224-896.734
TTM-899.958-3.643-896.315
YOY-1,728.150-4.753-1,723.397
5Y-1,177.538-8.014-1,169.524
10Y-1,413.541-8.616-1,404.925
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Clinuvel is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 5.62 means the investor is paying $5.62Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 4.344. Based on the equity, the company is fair priced.
  • The MRQ is 5.617. Based on the equity, the company is overpriced. -1
  • The TTM is 5.617. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.344MRQ5.617-1.273
MRQ5.617TTM5.6170.000
TTM5.617YOY5.979-0.362
TTM5.6175Y15.283-9.666
5Y15.28310Y14.267+1.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.3441.798+2.546
MRQ5.6171.902+3.715
TTM5.6172.234+3.383
YOY5.9792.416+3.563
5Y15.2833.557+11.726
10Y14.2674.120+10.147
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets193,714
Total Liabilities29,082
Total Stockholder Equity164,631
 As reported
Total Liabilities 29,082
Total Stockholder Equity+ 164,631
Total Assets = 193,714

Assets

Total Assets193,714
Total Current Assets189,618
Long-term Assets4,096
Total Current Assets
Cash And Cash Equivalents 156,814
Short-term Investments 132,946
Net Receivables 22,215
Other Current Assets 1,070
Total Current Assets  (as reported)189,618
Total Current Assets  (calculated)313,045
+/- 123,427
Long-term Assets
Property Plant Equipment 2,851
Goodwill 185
Intangible Assets 185
Other Assets 1,060
Long-term Assets  (as reported)4,096
Long-term Assets  (calculated)4,281
+/- 185

Liabilities & Shareholders' Equity

Total Current Liabilities25,495
Long-term Liabilities3,588
Total Stockholder Equity164,631
Total Current Liabilities
Short-term Debt 301
Accounts payable 2,792
Other Current Liabilities 22,402
Total Current Liabilities  (as reported)25,495
Total Current Liabilities  (calculated)25,495
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt699
Other Liabilities 2,889
Long-term Liabilities  (as reported)3,588
Long-term Liabilities  (calculated)3,588
+/-0
Total Stockholder Equity
Common Stock151,849
Retained Earnings -9,774
Other Stockholders Equity 22,556
Total Stockholder Equity (as reported)164,631
Total Stockholder Equity (calculated)164,631
+/-0
Other
Capital Stock151,849
Cash and Short Term Investments 156,814
Common Stock Shares Outstanding 51,816
Liabilities and Stockholders Equity 193,714
Net Debt -155,814
Net Invested Capital 164,631
Net Tangible Assets 164,446
Net Working Capital 164,123
Property Plant and Equipment Gross 5,204
Short Long Term Debt Total 1,000



6.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
15,441
13,769
10,520
8,066
10,247
10,056
17,071
67,825
54,971
41,614
29,507
20,165
15,995
15,815
17,154
13,644
20,138
28,607
42,905
62,345
81,542
108,568
143,950
193,714
193,714143,950108,56881,54262,34542,90528,60720,13813,64417,15415,81515,99520,16529,50741,61454,97167,82517,07110,05610,2478,06610,52013,76915,441
   > Total Current Assets 
7,995
7,028
4,483
2,748
5,682
5,246
13,917
65,317
53,120
40,594
29,158
19,932
15,807
15,668
17,039
13,575
19,974
28,470
42,269
61,153
75,156
102,848
140,583
189,618
189,618140,583102,84875,15661,15342,26928,47019,97413,57517,03915,66815,80719,93229,15840,59453,12065,31713,9175,2465,6822,7484,4837,0287,995
       Cash And Cash Equivalents 
7,927
6,981
4,414
2,612
5,480
4,763
8,606
33,842
25,752
21,711
19,415
12,178
12,719
12,569
14,626
10,572
13,845
23,752
36,198
54,269
66,747
82,691
121,509
156,814
156,814121,50982,69166,74754,26936,19823,75213,84510,57214,62612,56912,71912,17819,41521,71125,75233,8428,6064,7635,4802,6124,4146,9817,927
       Short-term Investments 
0
0
0
0
0
0
2,024
28,512
25,048
16,043
7,588
5,321
454
0
0
0
0
0
0
28,525
41,095
45,550
94,100
132,946
132,94694,10045,55041,09528,5250000004545,3217,58816,04325,04828,5122,024000000
       Net Receivables 
57
35
30
31
78
137
233
241
616
212
363
974
1,007
1,743
1,585
1,960
4,824
3,239
5,090
4,156
6,613
16,089
16,202
22,215
22,21516,20216,0896,6134,1565,0903,2394,8241,9601,5851,7431,0079743632126162412331377831303557
       Other Current Assets 
0
13
39
106
0
47
40
0
0
0
0
0
0
0
0
70
223
237
339
592
509
882
1,039
1,070
1,0701,03988250959233923722370000000004047010639130
   > Long-term Assets 
7,446
6,741
6,037
5,318
4,565
4,810
3,154
2,508
1,851
1,020
349
233
188
146
114
69
165
137
636
1,193
6,386
5,719
3,367
4,096
4,0963,3675,7196,3861,193636137165691141461882333491,0201,8512,5083,1544,8104,5655,3186,0376,7417,446
       Property Plant Equipment 
94
116
141
147
120
249
222
332
431
357
322
215
179
146
114
69
165
137
169
707
2,389
2,603
2,700
2,851
2,8512,7002,6032,3897071691371656911414617921532235743133222224912014714111694
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185
185
185
185
185
185
185185185185185185000000000000000000
       Intangible Assets 
7,352
6,624
5,896
5,171
4,445
4,561
2,932
2,176
1,420
663
28
18
9
0
0
0
0
0
0
185
185
185
185
185
185185185185185000000918286631,4202,1762,9324,5614,4455,1715,8966,6247,352
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282
301
3,812
2,931
482
1,060
1,0604822,9313,812301282000000000000000000
> Total Liabilities 
124
318
211
535
1,392
2,601
3,082
2,433
3,156
4,563
3,081
3,757
2,358
1,976
1,726
2,439
2,304
3,163
3,489
5,166
7,873
9,830
18,390
29,082
29,08218,3909,8307,8735,1663,4893,1632,3042,4391,7261,9762,3583,7573,0814,5633,1562,4333,0822,6011,392535211318124
   > Total Current Liabilities 
124
318
211
535
1,370
2,577
3,067
2,428
3,147
4,544
3,040
3,717
2,339
1,946
1,718
2,435
2,288
3,148
3,471
4,960
6,660
8,707
13,732
25,495
25,49513,7328,7076,6604,9603,4713,1482,2882,4351,7181,9462,3393,7173,0404,5443,1472,4283,0672,5771,370535211318124
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
261
212
258
315
301
3013152582122610000000000000000000
       Accounts payable 
115
291
157
466
1,180
2,346
2,535
1,597
734
2,056
569
1,697
839
184
178
261
231
579
429
1,500
1,430
2,324
259
2,792
2,7922592,3241,4301,5004295792312611781848391,6975692,0567341,5972,5352,3461,180466157291115
       Other Current Liabilities 
9
27
54
70
191
231
532
831
2,413
2,488
2,471
2,020
1,500
1,762
1,540
2,175
2,057
2,568
3,042
3,199
5,018
6,125
13,158
22,402
22,40213,1586,1255,0183,1993,0422,5682,0572,1751,5401,7621,5002,0202,4712,4882,4138315322311917054279
   > Long-term Liabilities 
0
0
0
0
22
24
15
5
9
19
41
40
19
29
8
3
15
15
18
205
1,213
1,123
4,658
3,588
3,5884,6581,1231,213205181515382919404119951524220000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
3
15
15
18
34
106
78
3,717
2,889
2,8893,71778106341815153800000000000000
> Total Stockholder Equity
15,317
13,451
10,310
7,531
8,855
7,454
13,989
65,392
51,815
37,051
26,426
16,408
13,637
13,839
15,428
11,205
17,796
25,386
39,416
57,180
73,669
98,737
125,559
164,631
164,631125,55998,73773,66957,18039,41625,38617,79611,20515,42813,83913,63716,40826,42637,05151,81565,39213,9897,4548,8557,53110,31013,45115,317
   Common Stock
15,692
15,382
15,382
16,580
25,494
35,123
52,726
112,813
113,222
113,221
113,228
113,339
119,323
126,710
133,567
138,465
146,765
148,413
148,615
151,314
151,849
151,849
151,849
151,849
151,849151,849151,849151,849151,314148,615148,413146,765138,465133,567126,710119,323113,339113,228113,221113,222112,81352,72635,12325,49416,58015,38215,38215,692
   Retained Earnings -9,774-38,402-58,130-80,037-95,487-112,681-125,847-133,063-129,958-119,577-114,122-107,507-100,145-88,971-78,337-63,172-49,066-39,890-27,668-16,639-9,050-5,073-1,932-374
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
1
1
0
0
0
0
0
0
0
0
0
0
0
1,438
2,698
4,095
2,820
3,482
1,352
1,850
5,018
12,112
22,556
22,55612,1125,0181,8501,3523,4822,8204,0952,6981,43800000000000110



6.3. Balance Sheets

Currency in AUD. All numbers in thousands.




6.4. Cash Flows

Currency in AUD. All numbers in thousands.




6.5. Income Statements

Currency in AUD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue78,321
Cost of Revenue-8,790
Gross Profit69,53269,532
 
Operating Income (+$)
Gross Profit69,532
Operating Expense-25,429
Operating Income48,77144,102
 
Operating Expense (+$)
Research Development1,268
Selling General Administrative22,567
Selling And Marketing Expenses-
Operating Expense25,42923,835
 
Net Interest Income (+$)
Interest Income3,906
Interest Expense-3,193
Other Finance Cost-0
Net Interest Income713
 
Pretax Income (+$)
Operating Income48,771
Net Interest Income713
Other Non-Operating Income Expenses-
Income Before Tax (EBT)45,57948,008
EBIT - interestExpense = 45,579
45,579
33,797
Interest Expense3,193
Earnings Before Interest and Taxes (EBIT)48,77148,771
Earnings Before Interest and Taxes (EBITDA)49,561
 
After tax Income (+$)
Income Before Tax45,579
Tax Provision-14,974
Net Income From Continuing Ops30,60530,605
Net Income30,605
Net Income Applicable To Common Shares30,605
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses34,219
Total Other Income/Expenses Net763-713
 

Technical Analysis of Clinuvel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clinuvel. The general trend of Clinuvel is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clinuvel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Clinuvel Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.51 < 9.51 < 9.51.

The bearish price targets are: 8.78 > 8.78 > 8.78.

Tweet this
Clinuvel Pharmaceuticals Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages